Olaratumab

• CAT Number: I041616
• CAS Number: 1024603-93-7
• Purity: ≥95%

Olaratumab (IMC-3G3; LY3012207) is an anti-platelet-derived growth factor receptor alpha (PDGFRα) human monoclonal IgG1 antibody with antitumor activity[1].
IMC-3G3 (100 μg/mL, 72 h) blocked PDGFRα phosphorylation in SKOV3-ip1 cells. And the combined treatment of IMC-3G3 and docetaxel significantly induced apoptosis in SKOV3-ip1 and HeyA8 cell lines[1].
IMC-3G3 (i.p., 40 mg/kg, three times per week, 6 weeks) in SKOV3-ip1 tumor-bearing mice, compared with the control group, IMC-3G3 treatment alone had no obvious anti-tumor effect, while in HeyA8 tumor-bearing mice, IMC-3G3 monotherapy showed a significant anti-tumor effect compared with the control group, with a tumor reduction rate of 62%[1].

Reference

[1]. Koji Matsuo, et al. Platelet-derived growth factor receptor alpha (PDGFRα) targeting and relevant biomarkers in ovarian carcinoma. Gynecol Oncol. 2014 Jan;132(1):166-75. 
 [Content Brief]